I received a bachelor’s degree in laser physics from Beijing (Peking) University in China and a master’s degree in accelerator physics from Sam Houston State University in Texas. With support from a U.S. Department of Defense Breast Cancer Research Predoctoral fellowship, I obtained a second master’s degree and a doctorate in biomedical engineering from the University of Texas Southwestern Medical Center at Dallas, specializing in magnetic resonance imaging (MRI). My doctoral research focused on measuring breast cancer oximetry (oxygen saturation) using fMRI. Subsequently, I completed a postdoctoral research fellowship in the Department of Radiation Oncology at Stanford University School of Medicine. My research focused on modulated electron radiation therapy in breast cancer treatment.
My current research interests are broad and interdisciplinary, including medical imaging, medical instrumentation, modern radiation oncology, and diagnostic radiology. I welcome researchers and students to contact me for possible research collaborations and thesis and dissertation projects.
Doctors and faculty members often work with pharmaceutical, device, biotechnology, and life sciences companies, and other organizations outside of MSK, to find safe and effective cancer treatments, to improve patient care, and to educate the health care community.
MSK requires doctors and faculty members to report (“disclose”) the relationships and financial interests they have with external entities. As a commitment to transparency with our community, we make that information available to the public.
Yulin Song discloses the following relationships and financial interests:
No disclosures meeting criteria for time period
The information published here is for a specific annual disclosure period. There may be differences between information on this and other public sites as a result of different reporting periods and/or the various ways relationships and financial interests are categorized by organizations that publish such data.
This page and data include information for a specific MSK annual disclosure period (January 1, 2021 through disclosure submission in spring 2022). This data reflects interests that may or may not still exist. This data is updated annually.